Lilly announces superiority of Taltz versus TREMFYA in IXORA-R trial

This article was originally published here

The IXORA-R trial is the first completed head-to-head (H2H) trial between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as

The post Lilly announces superiority of Taltz versus TREMFYA in IXORA-R trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply